[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thermal-ablation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thermal-ablation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100495115","ultrasound-and-cytological-evaluation-3-years-after-radiofrequency-thermal-ablation-of-benign-thyroid-nodules--a-prospective-exploratory-cohort-of-180-nodules-100495115",false,"NCT05726981","Ultrasound and Cytological Evaluation 3 Years After Radiofrequency Thermal Ablation of Benign Thyroid Nodules : a Prospective Exploratory Cohort of 180 Nodules","CYTOTHYRAF","Inclusion Criteria:\n\n1. Patients \\> 18 years old\n2. Carrier of a benign thyroid nodule that has undergone radiofrequency thermoablation 36 months previously ± 12 months +\u002F- 1 month, whether the nodule is stable, progressing or decreasing in volume during the screening period and\u002For on the day of inclusion.\n3. Obtaining written informed consent\n4. Affiliation to a social security system (excluding AME)\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women\n2. Previous alcohol use\n3. Patients on anti-vitamin K anticoagulants\n4. Patients on direct oral anticoagulants\n5. Persons deprived of liberty by judicial or administrative decision\n6. Persons under forced psychiatric care\n7. Persons admitted to a health or social institution for purposes other than research\n8. Persons of full age who are under legal protection (guardianship or curatorship)\n9. Persons unable to express their consent\n10. Persons under a legal protection measure (there can be no derogation for this category)","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"NA","There is no scientific data on post-thermal ablation cytological aspects, but treated nodules that grow back significantly after a procedure justify a new cytology in order not to ignore a neoplastic process.\n\nThe EU-TIRADS classification usually used to stratify the risk of cancer (and to justify a fine needle aspiration biopsy) of thyroid nodules is not validated for nodules treated by thermal ablation (TA) (post-RF nodules). However, these nodules often acquire ultrasound criteria of suspicion making it necessary to develop an ultrasound stratification of the risk of malignancy specific to nodules treated by TA.\n\nThe objective of this work is to describe the ultrasound and cytological aspects of these treated nodules by performing a systematic assessment at 3 years after thermal ablation including systematic neck ultrasound and fine needle aspiration biopsy. Thus, an ultrasound and cytological atlas (Bethesda classification 2017) of nodules treated by thermal ablation will be constituted.",[26,27,28],"Thermal Ablation","Fine Needle Aspiration Biopsy","Thyroid Nodules","RECRUITING","2025-08-26",{"date":32,"type":33},"2025-09-03","ACTUAL",{"date":35,"type":33},"2023-06-29",{"date":37,"type":20},"2026-04",{"name":39,"class":40},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100576924","surveillance-intervals-after-piecemeal-resection-of-non-pedunculated-colorectal-lesions-20mm-100576924","NCT06791616","Surveillance Intervals After Piecemeal Resection of Non-pedunculated Colorectal Lesions ≥20mm","Evaluation of Surveillance Intervals After Piecemeal Resection of Non-pedunculated Colorectal Lesions ≥20mm: SCARFACE Clinical Trial","Inclusion Criteria:\n\n* Patients with a single non-pedunculated colorectal lesion (NPCL) ≥20 mm that has been resected piecemeal and treated with thermal ablation (using snare tip or argon plasma) at the margins as prophylaxis against recurrence, and who are awaiting the initiation of specific endoscopic follow-up.\n* Complete colonoscopy with adequate or excellent bowel preparation performed within the last 6 months prior to the resection of the index lesion.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Resection performed using a cold snare technique due to the high risk of recurrence.\n* Histology of the lesion showing malignancy: colorectal cancer with submucosal invasion, regardless of invasion depth in microns.\n* Absence of information regarding the grade of dysplasia of the index lesion.\n* Personal history of colorectal cancer.\n* Incomplete endoscopic resection of the index lesion or any other polyps present in the patient.\n* When the endoscopist performing the index colonoscopy expresses doubts about whether the resection was complete.\n* Index lesion with prior attempted resection.\n* Hereditary cancer syndromes (e.g., adenomatous or serrated polyposis syndromes, Lynch syndrome, etc.).\n* Inflammatory bowel disease.\n* Severe comorbidities with reduced life expectancy.\n* Pregnancy.\n* Ongoing cytotoxic treatment or radiotherapy for a malignant disease.","85 Years",{"count":51,"type":20},746,[23],"Intensive endoscopic surveillance following piecemeal resection of non-pedunculated colorectal lesions (NPCL) ≥20 mm is the current standard of care, given the high recurrence rate of these lesions (15-30%). However, most recurrences are detected at 12 months, are small and unifocal, and can be easily resected endoscopically. Furthermore, thermal margin ablation has demonstrated a reduction in recurrence rates to 5-6%, highlighting the need to optimize current surveillance protocols, which are costly, invasive, and impose a significant clinical burden.\n\nThe multicenter SCARFACE clinical trial aims to evaluate whether a reduced surveillance protocol (at 12 and 48 months) is non-inferior to the standard protocol (at 6, 12, and 48 months) in terms of recurrence rates, using a predefined non-inferiority margin. This non-inferiority design aims to determine if the reduced protocol maintains acceptable efficacy while reducing clinical workload and minimizing risks and discomfort associated with intensive follow-up.\n\nPatients will be randomized in a 1:1 ratio into the two surveillance protocols, with an estimated sample size of 746 lesions. The primary objective is to compare the cumulative incidence of recurrence at 12 months. Secondary objectives include characterizing recurrences, assessing complications associated with endoscopic treatments and evaluating the incidence of advanced colorectal lesions. The findings of this study are expected to directly impact clinical guidelines and routine practice, optimizing resource utilization and improving patient quality of life.",[55,56,57,58,59,60,26,61],"Colorectal Neoplasms","Adenoma Colon","Colonic Polyps","Serrated Adenoma","Endoscopic Mucosal Resection","Non-pedunculated Lesions","Recurrence","NOT_YET_RECRUITING","2025-01-19",{"date":65,"type":33},"2025-01-24",{"date":67,"type":20},"2025-03-01",{"date":69,"type":20},"2030-05-31",{"name":71,"class":40},"Asociación Española de Gastroenterología",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":41},"100513240","a-study-of-factors-influencing-recurrence-after-thermal-ablation-of-papillary-thyroid-carcinoma-100513240","NCT05962892","A Study of Factors Influencing Recurrence After Thermal Ablation of Papillary Thyroid Carcinoma","Inclusion Criteria:\n\n①≥18 years old; ② Obtain informed consent; ③ Ultrasonography showed that malignant nodules were single, the maximum diameter of nodules was ≤1cm and the distance from the capsule was ≥2mm. ④ no lymph node metastasis or other extra-glandular metastasis in the neck; ⑤ PTC was confirmed by fine needle puncture pathology; ⑥ Patients who do not meet Article 3, who still strongly request thermal ablation while fully informing the patient of the risk of recurrence, and who have been clinically assessed to be technically capable of thermal ablation Exclusion Criteria:① Pregnant or lactating patients; ② Patients with other malignant tumors and not suitable for ablation by clinical evaluation; ③ Patients who cannot tolerate surgery; ④ Patients with cognitive impairment and other conditions who cannot accurately fill in thyroid-related questionnaires.",{"count":79,"type":20},600,"5 Years","OBSERVATIONAL","A prospective cohort of papillary thyroid carcinoma(PTC), patients who received thermal ablation in our hospital since February 2023 was established as the study object. Preoperative and postoperative demographic data, ultrasonography, other relevant laboratory tests, and thyroid disease-related scales such as fatigue, depression, and stress were collected. The influencing factors of PTC recurrence were analyzed.",[84,26],"Papillary Thyroid Carcinoma",[84,86,26,61],"cohort","2024-01-29",{"date":89,"type":33},"2024-01-30",{"date":91,"type":20},"2024-02-01",{"date":93,"type":20},"2028-02-28",{"name":95,"class":40},"Beijing Friendship Hospital"]